Search Results 651-660 of 18375 for alopecia
Recovery to ≤ Grade 1 of any clinically significant toxicity (excluding alopecia) rior to randomization. Subject must have adequate bone marrow, renal and ...
Grade > 2 toxicity (other than alopecia) continuing from prior anti-cancer therapy. History of non-compliance to medical regimens. Participating Mayo Clinic ...
... alopecia; Concurrent use of somatostatin analogs (SSTa) is allowed, provided that the patient is on a stable dose for at least two months and progressive ...
... alopecia) not requiring systemic treatment, or prior autoimmune conditions not expected to recur are eligible. History of interstitial lung disease. History ...
Patients should have improvement of any toxic effects of prior therapy (except alopecia, fatigue, and other non-reversible toxic effects such as neuropathy ...
All toxicities attributed to prior anti-cancer therapy other than nephropathy, neuropathy, hearing loss, alopecia and fatigue must have resolved to Grade 1 ...
... alopecia or other toxicities not considered a safety risk for the subject at the Investigator's discretion). 4. Subject has had major surgery within 14 days ...
... alopecia). Active uncontrolled bacterial, viral, or fungal infection requiring systemic therapy. Known history of testing positive for human ...
Patients must have recovered to CTCAE Grade 1 or better from any adverse events due to prior cancer therapy (with the exception of alopecia). Patient must ...
Toxicities due to prior therapy must be stable and recovered to Grade ≤ 1 (except for clinically nonsignificant toxicities such as alopecia). Age 18 or ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!